The 1,3-Beta-D-Glucan (BDG) test measures circulating (1→3)-β-D-glucan, a polysaccharide found in the cell walls of many fungi. At Biopassion Diagnostics, this assay is used as a supportive laboratory investigation when clinicians are evaluating possible invasive fungal infection, especially in people at elevated risk. It is an antigen-based blood test, not a DNA or genetic screening test.
- Call Anytime: +254 704 150555
- info@biopassiondiagnostics.co.ke
1 3BetaDGlucan BDG Test
Infection Testing
1 3BetaDGlucan BDG Test
KSh 36,000.00
Regular price
KSh 30,960.00
Current price
-14%
What Is the 1 3BetaDGlucan BDG Test?
(1→3)-β-D-glucan is a structural component of the cell wall of many medically important fungi. When an invasive fungal infection develops, fragments of this molecule can enter the bloodstream and be measured in serum.
The BDG test looks for elevated levels of this marker. It can help clinicians assess the possibility of infection with organisms such as Candida species, Aspergillus species, Fusarium species, and Pneumocystis jirovecii. It does not identify the exact species on its own.
Importantly, some fungi produce little or no detectable BDG. Cryptococcus species, Blastomyces species, and the Mucorales group (for example Mucor and Rhizopus) are generally not well detected by BDG assays. A negative BDG result therefore does not exclude every type of fungal disease.
Why Is This Test Performed?
Clinicians may request BDG testing to:
- Support the investigation of suspected invasive fungal infection in high-risk patients
- Contribute to early laboratory evidence while culture, imaging, or organism-specific tests are pending
- Help evaluate deep-seated fungal infection or fungemia when symptoms and host risk factors raise concern
- Add complementary information alongside microscopy, culture, antigen tests, PCR assays, and clinical assessment
BDG is typically used as an adjunct. It should not replace a full clinical work-up or organism-directed testing when those are indicated.
Who Should Consider This Test?
This test is most relevant for people in whom invasive fungal infection is a genuine clinical concern, including:
- Patients with significant immunosuppression, such as those receiving intensive chemotherapy or immunosuppressive therapy
- Haematology or oncology patients at risk of invasive candidiasis or aspergillosis
- Solid-organ or haematopoietic stem-cell transplant recipients under specialist care
- Critically ill patients with risk factors for invasive candidiasis
- Patients being evaluated for Pneumocystis jirovecii pneumonia when BDG forms part of the clinician’s planned investigation
- Individuals with persistent fever or systemic infection features in whom fungal disease remains in the differential diagnosis
It is not a general wellness, preventive screening, or routine DNA health test for people without relevant risk factors or clinical suspicion.
What Does the Test Detect or Measure?
The assay measures the concentration of (1→3)-β-D-glucan in the submitted specimen, most commonly serum.
Elevated circulating BDG may support the possibility of invasive infection with BDG-producing fungi. The result is quantitative or semi-quantitative depending on the laboratory method in use, and is interpreted against method-specific reference thresholds.
The test does not:
- Name the fungal species responsible
- Distinguish colonisation from invasive disease on its own
- Reliably detect Cryptococcus, Blastomyces, or Mucorales infections
- Replace culture, histopathology, imaging, or clinician judgement
Sample Requirements
For standard BDG assays, the usual specimen is serum obtained from a blood draw. Some laboratories also accept selected alternative specimen types in specific clinical contexts; availability depends on the method validated by the testing laboratory.
Commonly described specimen categories for BDG testing include:
- Serum (primary specimen for circulating BDG measurement)
- In selected protocols, bronchoalveolar lavage (BAL) fluid or cerebrospinal fluid (CSF), when clinically indicated and accepted by the laboratory
Collection and handling matter. Glucan contamination of tubes, reagents, or the collection environment can produce misleading elevations. Use laboratory-approved collection materials and follow the instructions provided at booking.
Do not assume home collection is available for every case; confirm collection arrangements with Biopassion Diagnostics when you book.
Test Preparation
No fasting is generally required for serum BDG testing.
Please tell your clinician and the laboratory about recent treatments or exposures that can affect interpretation, including:
- Recent haemodialysis, particularly with cellulose-containing membranes
- Recent administration of certain blood products such as albumin or intravenous immunoglobulins
- Recent major surgery with substantial exposure to glucan-containing gauze or surgical materials
- Current antifungal therapy and other relevant medications
Bring any clinical history, referral notes, or risk-factor information requested at booking so results can be interpreted in context.
How the Test Works
- Booking or test request — A clinician referral or patient booking is made with Biopassion Diagnostics, including relevant clinical details where available.
- Sample collection — A trained collector obtains the approved specimen, usually a blood sample for serum BDG testing, using laboratory-compatible materials.
- Laboratory analysis — The specimen is processed and analysed for (1→3)-β-D-glucan using the laboratory’s validated BDG method.
- Quality review — Results are checked against internal quality procedures before release.
- Report delivery — A confidential report is issued to the requesting clinician or authorised recipient.
- Clinical interpretation — Findings should be reviewed with the treating clinician together with symptoms, imaging, cultures, and other investigations.
What the Results May Show
Depending on the assay and reporting format, results may be described as below a decision threshold, indeterminate, or elevated/positive relative to laboratory cut-offs.
- An elevated or positive BDG result may support the possibility of invasive infection with a BDG-producing fungus, but it is not a standalone diagnosis.
- A result below the threshold may help reduce suspicion for certain invasive fungal infections, while remembering that some fungi are poorly detected by BDG testing.
- Borderline or discordant results may require repeat testing and correlation with clinical findings.
Results must always be interpreted alongside host risk factors, physical findings, imaging, microbiology, and other laboratory data. Biopassion Diagnostics does not provide a clinical diagnosis from this webpage; discuss your report with your healthcare provider.
Benefits or Clinical Value
When used appropriately, BDG testing can:
- Support earlier laboratory investigation of selected invasive fungal infections in at-risk patients
- Complement culture and organism-specific assays while those results are awaited
- Help clinicians refine the differential diagnosis in complex immunocompromised or critical-care settings
- Contribute information that may guide whether further antifungal evaluation or organism-directed testing is needed
Its greatest practical value is as part of a broader clinical assessment, not as an isolated screening tool.
Limitations and Important Considerations
- BDG is a supportive marker, not a definitive species-level diagnostic test.
- False-positive or misleading elevations can occur after recent haemodialysis with cellulose membranes, exposure to glucan-containing surgical materials, or administration of certain fractionated blood products such as albumin or immunoglobulins.
- Some bacterial infections and mucosal barrier injury have also been associated with non-fungal BDG elevations in the literature; clinical correlation is essential.
- Cryptococcus, Blastomyces, and Mucorales infections may be missed because these organisms produce little or no BDG.
- Sample contamination with environmental glucans can distort results.
- Sensitivity and specificity vary across studies and patient populations; serial testing and clinical context improve usefulness.
- Antifungal decisions should not be based on a single BDG result alone.
Frequently Asked Questions
-
Is the BDG test a DNA test?No. The 1,3-beta-D-glucan test measures a fungal cell-wall antigen in the specimen. It is not a genetic sequencing or DNA screening test.
-
What sample is usually required?Serum from a blood sample is the usual specimen for circulating BDG measurement. Confirm the exact collection requirements with Biopassion Diagnostics when booking, as accepted specimen types depend on the validated laboratory method.
-
Does a positive BDG result confirm invasive fungal infection?No. An elevated result can support clinical suspicion, but it must be interpreted with symptoms, risk factors, imaging, and other laboratory findings. False-positive elevations are well recognised.
-
Can BDG detect every fungal infection?No. Important exceptions include Cryptococcus, Blastomyces, and Mucorales (moulds such as Mucor and Rhizopus), which typically produce little or no detectable BDG.
-
Is fasting required?Fasting is generally not required. Tell the laboratory about recent dialysis, blood-product infusions, surgery involving glucan-containing materials, and antifungal medicines, as these can affect interpretation.
-
Who should interpret the report?A clinician familiar with your medical history should interpret the result. BDG is an adjunctive laboratory marker and is not intended for self-diagnosis.
Pricing
| Test Name | Current Price | Regular Price |
|---|---|---|
| 1 3BetaDGlucan BDG Test | KSh 30,960.00 | KSh 36,000.00 |
Book the 1 3BetaDGlucan BDG Test
Contact Biopassion Diagnostics to confirm sample requirements and schedule this test.
SKU: c9f0f895fb98 | Category: Infection Testing